VeriSeq PGS Kit- MiSeq

Improving IVF outcomes using PGT-A

Webshop log in
15049007 RH-101-1001 VeriSeq PGS Kit – MiSeq (96 samples)
  • Description: All reagents required to prepare 96 samples for sequencing on the MiSeq sequencing system for the application of PGT-A (PGS). 2 x SurePlex DNA Amplification Systems (50 reactions per kit) 1 x VeriSeq PGS Library Preparation Kit – PGS (96 samples) 1 x VeriSeq Index Kit-PGS (24 indexes, sufficient for 95 samples) 4 x MiSeq Reagent Kit v3-PGS (upto 24 reactions per kit)
15049008 RH-102-1001 MiSeq Reagent Kit v3-PGS (24 samples)
  • Description: Reagents required for sequencing 24 prepared libraries on the MiSeq system 1 x MiSeq Reagent Kit v3-PGS (upto 24 reactions per kit)

What is PGT-A?

PGT-A (Preimplantation Genetic Testing for Aneuploidy), formerly referred to as PGS (Preimplantation Genetic Screening) determines the chromosomal status of an embryo by screening all 23 chromosome pairs prior to transfer in an IVF cycle.

PGT-A may be appropriate for couples pursuing IVF due to a history of infertility or recurrent pregnancy loss because a major cause of IVF failure is aneuploidy — embryos with an abnormal number of chromosomes.1,2 Aneuploidy can occur in any embryo; however, the chances increase with maternal age.3, 4

How does it work?

  1. Following ovarian stimulation and egg retrieval, a single or a few cells are biopsied from the embryo.
  2. Embryos are screened for aneuploidy
  3. Those most likely to be euploid (normal number of chromosomes) are either transferred to the uterus or frozen for future use
  4. The chances of IVF success are improved4, 6, 7

Advantages of PGT-A

Selectively transferring embryos most likely to have a normal number of chromosomes (euploid) is important in reducing miscarriage rates and improving IVF success rates.4,5,6,7  PGT-A has the following benefits:

  • Mitigates several reproductive challenges associated with maternal age
  • Leads to greater implantation rates and improved IVF outcomes
  • Enables single embryo transfers with higher chance of success, reducing multiple births and the complications that can result from it

PGT-A can be performed using next-generation sequencing (NGS) using the VeriSeq PGS Solution on the MiSeq Sequencing Instrument.

Make advancements with PGT-A

Using Illumina technology, the VeriSeq PGS solution can screen all 24 chromosomes in as little as 12 hours for an accurate, efficient view of the number of chromosomes in an embryo.

VeriSeq PGS kit - MiSeq

The VeriSeq PGS Kit - MiSeq uses NGS on the Illumina MiSeq System to screen all 24 chromosomes for aneuploidy in a single assay. The assay can be used on a single-cell (blastomere biopsy) or a few cells (blastocyst biopsy) from an embryo. The VeriSeq PGS workflow goes from sample to result in approximately 12 hours.

The VeriSeq PGS Kit is designed for multiplexing up to 24 samples per run on the MiSeq System. When 24 samples are not available for a run, it is possible to run the assay in a low-throughput, fast-run mode (8-12 samples/run).

  • Industry-leading data quality: More than 90% of the world’s sequencing data is generated by Illumina sequencing by synthesis (SBS) chemistry*
  • Fast, streamlined workflow: Sample to answer in approximately 12 hours
  • High-throughput analysis: Screen up to 24 samples per run
  • Low input: NGS offers a highly sensitive method for screening embryos, requiring as little as 1 ng of DNA from a SurePlex DNA amplification reaction. DNA can be obtained from a blastomere biopsy, from a day 3 embryo, or from a trophectodermal (TE) biopsy from a blastocyst

*Data calculations on file. Illumina. Inc 2015

Time-lapse & PGT - Better together

Many clinics have seen the benefit of making time-lapse a standard of care for their patients. The same is true for Preimplantation Genetic Testing (PGT). The fact that there are two such widely implemented techniques has created some questions about which new technology will offer the best treatment options for improving clinical outcome. In this webinar Dr. Tine Qvistgaard Kajhøj shows how time-lapse and PGT can be used together to offer the best overall possibility for improving outcomes and clinical workflow.

Watch webinar

Are you a patient?

Learn more about how PGT-A may improve your chance of a successful pregnancy

Learn more


1. Centers for Disease Control and Prevention.Org Website Accessed March 11, 2016.
2. Scott RT, Ferry K, Su J, Tao X, Scott K, Treff NR. Comprehensive chromosome screening is highly predictive of the reproductive potential of human embryos: a prospective, blinded, nonselection study. Fertil Steril. 2012;97(4):870-875.
3. Ata B, Kaplan B, Danzer H, et al. Array CGH analysis shows that aneuploidy is not related to the number of embryos generated. Reprod Biomed Online. 2012;24:614–620.
4. Harton GL, Munne S, Surrey M, et al. Diminished effect of maternal age on implantation after preimplantation genetic diagnosis with array comparative genomic hybridization. Fertil Steril. 2013;100(6):1695–1703
5. Yang Z, Liu J, Collins GS, Salem SA, Liu X, et al. (2012) Selection of single blastocysts for fresh transfer via standard morphology assessment alone and with array CGH for good prognosis patients: results from a randomised pilot study. Mol Cytogenet 5: 24
6 Forman EJ, Hong KH, Ferry KM, et al. In vitro fertilization with single euploid blastocyst transfer: a randomized controlled trial. Fertil Steril. 2013;100(1):100–107.
7. Grifo JA, Hodes-Wertz B, Lee HL, Amperloquio E, Clarke-Williams M, Adler A. Single thawed euploid embryo transfer improves IVF pregnancy, miscarriage, and multiple gestation outcomes and has similar implantation rates as egg donation. J Assist Reprod Genet. 2013;30(2):259–264

How to use this product

VeriSeq PGS Kit- MiSeq


Validation of the VeriSeqPGS Solution

VeriSeq PGS Kit- MiSeq


Rapid aneuploidy screening using the MiSeq System

Do you have a question about this product?

Contact us

Find your local Vitrolife representative

Contact us